Table 1 Characteristics of 73 critically ill COVID-19 patients dying during ICU stay
From: Causes and timing of death in critically ill COVID-19 patients
COVID-19 patients dying in ICU N = 73 | |
|---|---|
Patient’s characteristics and ICU scores | |
Male sex | 56 (77) |
Age, years | 68 [62–73] |
SAPS II upon ICU admission | 37 [29–45] |
SOFA upon ICU admission | 4 [3–8] |
Main comorbidities | |
Arterial hypertension | 52 (71) |
Diabetes mellitus | 35 (48) |
Ischemic cardiopathy | 10 (14) |
Chronic respiratory disease | 18 (25) |
Immunocompromised status | 18 (25) |
Main delays | |
Days between disease onset and ICU admission | 8 [6–11] |
> 7 days between disease onset and ICU admission | 51 (70) |
Biological data upon ICU admission | |
D-dimers (ng/mL) | 2505 [1555–5877] |
Fibrinogen (g/L) | 7.3 [5.6–8.5] |
Treatment administered upon ICU admission | |
Glucocorticoids | 35 (48) |
Intermediate or full-dose thromboprophylaxis | 53 (73) |
Antibiotic therapy for bacterial co-infection at ICU admission | 20 (27) |
Antiviral drugs (lopinavir-ritonavir or remdesivir) | 0 (0) |
Tocilizumab | 0 (0) |
Outcome in the ICU | |
Invasive mechanical ventilation (IMV) | 71 (97) |
Days between ICU admission and IMV | 2 [1–4] |
Days between disease onset and IMV | 11 [8–14] |
Ventilator associated pneumonia | 47 (64) |
Prone positioning | 62 (85) |
Extra corporal membrane oxygenation | 3 (4) |
Tracheostomy | 2 (3) |
Renal replacement therapy | 26 (36) |
Vasopressor support | 64 (88) |
Thrombotic events during ICU stay | 26 (36) |
Hemorrhagic events during ICU stay | 17 (23) |
Delay between ICU admission and death, days | 14 [9–23] |